PIM
PRQR icon

Platinum Investment Management’s ProQR Therapeutics PRQR Stock Holding History

Platinum Investment Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2M Hold
1,235,514
– – 0.5% 64
2025
Q4 		$2.5M Hold
1,235,514
– – 0.58% 57
2025
Q3 		$2.63M Sell
1,235,514
-215,455
-15% -$471K 0.17% 58
2025
Q2 		$2.96M Sell
1,450,969
-87,278
-6% -$142K 0.2% 49
2025
Q1 		$2.05M Hold
1,538,247
– – 0.12% 53
2024
Q4 		$4.08M Buy
+1,538,247
New +$4.88M 0.24% 43

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Platinum Investment Management's PRQR Position: Q1 2026 in Review

Platinum Investment Management held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 1,235,514 shares worth $2M. The position accounts for 0.5% of the portfolio, ranked #64.

Platinum Investment Management first reported a position in PRQR in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.08M in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Platinum Investment Management held 1,235,514 shares of ProQR Therapeutics worth $2M as of Q1 2026.
  • Platinum Investment Management left its ProQR Therapeutics share count unchanged in Q1 2026.
  • ProQR Therapeutics made up 0.5% of Platinum Investment Management's portfolio in Q1 2026, its #64 holding.
  • Platinum Investment Management first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Platinum Investment Management's ProQR Therapeutics position peaked at $4.08M in Q4 2024.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Platinum Investment Management's 13F filing for Q1 2026, filed 14 May 2026.